Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025Presented ...
This column reports on several recent significant decisions from the United States District Court for the Eastern District of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback